Genius Group Ltd. (GNS)
AMEX AMEX Primary 
XSTU 
Genus jumps 11% as new Chinese pig JV formed at end of 'landmark' year
Genus PLC (LSE:GNS) shares leapt almost 11% higher on Thursday morning after the livestock genetics group sealed a new China deal and announced a 24% increase in annual profits. The FTSE 250-listed group reported adjusted profit before tax of £74.3 million, up 38% at constant currency rates, boosted by broad-based growth across its porcine genetics business (PIC) and profitability improvements in bovine (ABS).
Zang warns "Genius Act" will trigger hyperinflation, sees "globally coordinated" gold confiscation ahead
Jeremy Szafron joins Kitco News as an anchor and producer from Kitco's Vancouver bureau. Jeremy is a seasoned journalist with a diverse background covering entertainment, current affairs and finance.
Broker lifts target price for Genus as turnaround gathers pace
Shore Capital has nudged up its valuation for animal genetics group Genus PLC (LSE:GNS), raising the fair value from 2,750p to 2,900p and sticking with a buy recommendation ahead of full-year results next month. The upgrade reflects stronger-than-expected cash conversion, faster debt reduction and improving margins, particularly in the bovine (ABS) division.
Genus up 7% after strong trading update; broker reckons there's further to go
Genus PLC's (LSE:GNS) shares rose 7% following a strong trading update for the year ending June 2025. The animal genetics group reported underlying performance in line with expectations and highlighted double-digit profit growth in its PIC pig breeding business.
Coinbase: Genius Act Deep Dive
Coinbase remains a strong buy due to resilient fundamentals, diversified revenue, and robust growth in subscriptions and services, even amid crypto market volatility. The GENIUS Act is a major catalyst, providing regulatory clarity for stablecoins, unlocking institutional and corporate adoption, and expanding Coinbase's total addressable market. Despite high valuation premiums, I believe Coinbase's rapid revenue growth and stablecoin-driven margin expansion justify the upside potential, with 81% share price appreciation possible.
Strategy's 3rd Preferred, Why STRD Is The Genius Gear In Its Bitcoin Accumulation Engine
MicroStrategy's new STRD preferred stock offers a 10% yield, targeting yield-seeking, risk-tolerant investors. STRD sits below STRF and STRK in seniority, increasing risk but also enhancing the creditworthiness and market appeal of senior preferreds. This capital stack innovation will allow MSTR to raise funds at lower costs, maximizing Bitcoin accumulation while minimizing dilution for common shareholders.
Genius Sports: Riding The Betting Data Wave With Earnings Re-Rating In Sight
Genius Sports powers the global sports betting ecosystem with exclusive data partnerships and a vertically integrated, high-margin business model. Robust top-line growth, expanding margins, and a healthy balance sheet justify the current premium valuation, despite early-stage profitability. Key risks include client concentration, contract renewals, regulatory hurdles, and valuation sensitivity, but the long-term growth outlook remains compelling.
Genius Sports: Data Moat With Improving Unit Economics
Genius Sports is a leading sports data provider with exclusive rights, benefiting from the booming sports betting industry and recurring revenue streams. GENI's fixed-cost, high-margin business model enables strong operating leverage, margin expansion, and positive cash flow as revenue grows without significant cost increases. The stock trades at a discount to peers despite higher EBITDA growth, creating an attractive mispricing and compelling Buy opportunity.
So Simple, It's Genius: 3 Dividend Stocks You'll Wish You Bought Sooner
I value businesses that thrive on simplicity, where even mediocre leadership can't break them. Complexity often leads to failure, not wealth. There's real, lasting wealth in boring, stable businesses. From school carpet tools to regional billboards, simplicity can be wildly profitable. That's why I focus on dividend-paying companies with simple models, steady growth, and strong balance sheets, designed to build wealth, not stress.
Genius Group Limited (GNS) 2024 Financial Results & 2025 Guidance Call Transcript
Genius Group Limited (NYSE:GNS ) 2024 Financial Results & 2025 Guidance Call April 30, 2025 8:00 AM ET Company Participants Roger Hamilton – Chief Executive Officer Gaurav Dama – Chief Financial Officer Conference Call Participants Roger Hamilton All right, thank you everyone for joining us today on our Genius Group Investor Call. I am Roger Hamilton, the Chairman and CEO of Genius Group, and I'm now going to start the presentation with sharing my screen and I am joined here today by Gaurav Dama, our Chief Financial Officer, where we're going to be sharing with you our 2024 full year results together with updates on our AI-Powered Genius Curriculum, our Genius City model, Genius Treasury strategy and a variety of current legal cases and guidance for 2025.
Genus FDA green light a “hugely significant landmark"
Genus PLC (LSE:GNS) shares jumped 24% on Wednesday after the US Food and Drug Administration approved its gene-edited PRRS-resistant pigs for use in the American food chain, a decision analysts at Panmure Liberum called a “hugely significant landmark”. The move marks the first regulatory green light for a breakthrough genetic edit that aims to protect pigs from porcine reproductive and respiratory syndrome (PRRS), one of the most damaging diseases in global pork production.
Genus shares leap 22% after FDA clears gene-edited pigs for US food chain
Shares in Genus PLC (LSE:GNS) surged 22% on Wednesday after the US Food and Drug Administration approved the company's gene-edited pigs for use in the American food supply. It marks a major breakthrough for the FTSE 250 animal genetics group, which has spent years developing pigs resistant to PRRS, a disease that has long plagued the global pork industry.
